Background: Schistosomiasis is a chronic neglected tropical disease of poverty caused by blood dwelling trematodes of Schistosoma species. Praziquantel (PZQ) is the current drug of choice for the treatment of human schistosomiasis. The existence of Praziquantel resistance by Schistosoma species is a threat and an alarm for strict monitoring and periodic evaluation of its efficacy. Method: We searched PubMed, PubMed Center, Google Scholar, Web of Science, Google, Science Direct, MEDLINE and proceedings of a professional association to identify studies published in English and assessed the efficacy of Praziquantel against Schistosoma mansoni infection in children. Studies reporting the efficacy of Praziquantel in both adult and children as study participants and studies which investigated the efficacy of Praziquantel combined with other antischistosomal drugs were excluded. Result: Since there was significant heterogeneity, the random effect model was used. A total of 9 papers involving 1,412 participants, that assessed the cure rate and 8 papers that assessed egg reduction rate of Praziquantel were included in the meta-analysis. The pooled cure rate of Praziquantel was 86.65% with 95% CI; 83.4-93.9. There was high heterogeneity (I2=93.4%). Subgroup analysis showed slightly higher Cure rate of Praziquantel in Amhara regional state compared to Oromia regional state (88.58% vs 84.79%). The egg reduction rate was 87.95% and 99.85% using geometric and arithmetic mean of egg count respectively. The prevalence of Schistosoma mansoni decreased from 55.77% to 11.29% after administration of Praziquantel. Conclusion: According to the result of this review, standard dose of Praziquantel was effective against Schistosoma mansoni infection among children in Ethiopia. The cure rate of Praziquantel was slightly higher in Amhara regional state compared to Oromia regional state. The drug showed a great reduction in egg count and intensity of infection.
| Published in | International Journal of Immunology (Volume 8, Issue 4) |
| DOI | 10.11648/j.iji.20200804.11 |
| Page(s) | 61-69 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Praziquantel, Schistosoma mansoni, Efficacy, Ethiopia
| [1] | Karunamoorthi K, Almalki M, Ghailan K. Schistosomiasis: A neglected tropical disease of poverty: A call for intersectoral mitigation strategies for better health. J Health Res Rev. 2018; 5 (1): 1. |
| [2] | WHO. WHO Weekly epidemiological record. 2012; 87 (4): 37–44. |
| [3] | World Health Organization, Department of Control of Neglected Tropical Diseases. Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases. 2017. |
| [4] | WHO. Preventive chemotherapy and transmission control databank for schistosomiasis. Available from: available at http://www.who.int/neglected_diseases/preventive_chemotherapy/ sch/en/index.html |
| [5] | Stefanie Knopp, So¨ren L Becker, Katrin J Ingram, Jennifer Keiser, Ju¨rg Utzinger. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev Anti Infect Ther. 2013; Available from: www.expert-reviews.com |
| [6] | CDC. Parasite. Schistosomiasis. 2012; Available from: http://www.cdc.gov/parasites/ schistosomiasis/ |
| [7] | Wang W, Wang L, Liang Y-S. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012; 111 (5): 1871–7. |
| [8] | King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of Repeated Praziquantel Dosing in the Treatment of Schistosomiasis in High-Risk Communities in Africa: A Systematic Review. Keiser J, editor. PLoS Negl Trop Dis. 2011; 5 (9): e1321. |
| [9] | Muhubiri Kabuyaya, Moses John Chimbari, Samson Mukaratirwa. Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in subSaharan Africa: a systematic review. Infect Dis Poverty. 2018; 7: 73. |
| [10] | Chai J-Y. Praziquantel Treatment in Trematode and Cestode Infections: An Update. Infect Chemother. 2013; 45 (1): 32. |
| [11] | M. G. Chipeta, B. Ngwira, L. N. Kazembe. Analysis of schistosomiasis haematobium infection prevalence and intensity in Chikhwawa, Malawi: an application of a two part mode. PLoS Negl Trop Dis. 2013; 7 (3): e2131. |
| [12] | L. Savioli, A. F. Gabrielli, A. Montresor, L. Chitsulo, D. Engels. Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54⋅19. Parasitology. 2009; 136 (13): 1677–1681. |
| [13] | WHO. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelmintic Drugs in Control Interventions. Man Health Prof Programme Manag World Health Organ Geneva Switz. 2006; |
| [14] | Fallon PG, Sturrock RF, Capron A, Niang M, Doenhoff MJ. Short Report: Diminished Susceptibility to Praziquantel in a Senegal Isolate of Schistosoma mansoni. Am J Trop Med Hyg. 1995; 53 (1): 61–2. |
| [15] | Ismail M, Metwally A, Farghaly A, Bruce J, Tao L-F, Bennett JL. Characterization of Isolates of Schistosoma mansoni from Egyptian Villagers that Tolerate High Doses of Praziquantel. Am J Trop Med Hyg. 1996; 55 (2): 214–8. |
| [16] | Nebiyu Negussu, Birhan Mengistu, Biruck Kebede, Kebede Deribe, Ephrem Ejigu, Gemechu Tadesse, et al. Ethiopia Schistosomiasis and Soil-Transmitted Helminthes Control Programme: Progress and Prospects. Ethiop Med J. 2017; 55 (1): 75–80. |
| [17] | Hussen S, Assegu D, Shimelis T. Prevalence of Schistosoma mansoni infection in Ethiopia: A systematic review and meta-analysis. Microbiology; 2019. Available from: http://biorxiv.org/lookup/doi/10.1101/610113 |
| [18] | Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1–12. |
| [19] | Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. BMJ. 1997 Dec 6; 315 (7121): 1533–7. |
| [20] | Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 (11): 1539–58. |
| [21] | Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414): 557–60. |
| [22] | Tang J-L, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. 2000; 53 (5): 477–84. |
| [23] | Ried, K. Interpreting and understanding meta-analysis graphs: a practical guide. Aust Fam Physician. 2006; 35 (8): 635–8. |
| [24] | Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151 (4): 264–9, W64. |
| [25] | Tadesse Dejenie, Tsehaye Asmelash, Mahmud Abdelkadir. Efficacy of Praziquantel in Treating Schistosoma Mansoni Infected School Children in Tumuga and Waja, North Ethiopia. MEJS). 2010; 2 (2): 3–11. |
| [26] | Kemal M, Tadesse G, Esmael A, Abay SM, Kebede T. Schistosoma mansoni infection among preschool age children attending Erer Health Center, Ethiopia and the response rate to praziquantel. BMC Res Notes. 2019 Dec; 12 (1): 211. |
| [27] | Bajiro M, Dana D, Ayana M, Emana D, Mekonnen Z, Zawdie B, et al. Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia. Parasit Vectors. 2016; 9 (1): 560. |
| [28] | Getinet Degu, Getahun Mengistu, Janet Jones. Praziquantel efficacy against schistosomiasis mansoni in schoolchildren in north-west Ethiopia. Trans R Soc Trop Med Hyg. 2002; 96: 444–5. |
| [29] | Reta B, Erko B. Efficacy and side effects of praziquantel in the treatment for Schistosoma mansoni infection in school children in Senbete Town, northeastern Ethiopia. Trop Med Int Health. 2013; 18 (11): 1338–43. |
| [30] | Erko B, Degarege A, Tadesse K, Mathiwos A, Legesse M. Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia. Asian Pac J Trop Biomed. 2012; 2 (3): 235–9. |
| [31] | Samuel Haile, * Lemu Golassa, Zeleke Mekonnen. Prevalence of Schistosoma mansoni and effectiveness of Praziquantel in school children in Finchaa valley, Ethiopia. J Parasitol Vector Biol. 2012; 4 (3): 25–30. |
| [32] | Woldegerima E, Bayih AG, Tegegne Y, Aemero M, Jejaw Zeleke A. Prevalence and Reinfection Rates of Schistosoma mansoni and Praziquantel Efficacy against the Parasite among Primary School Children in Sanja Town, Northwest Ethiopia. J Parasitol Res. 2019; 2019: 1–8. |
| [33] | Tesfie A, Getnet G, Abere A, Yihenew G, Belete Y, Kassa M, et al. Praziquantel is an effective drug for the treatment of Schistosoma Mansoni infection among school-aged children in Northwest Ethiopia. Trop Med Health. 2020; 48 (1): 28. |
| [34] | Andrews P, Thomas H, Pohlke R, Seubert Jür. Praziquantel. Med Res Rev. 1983; 3 (2): 147–200. |
| [35] | Jean T Coulibaly, Gordana Panic, Kigbafori D Silué, Jana Kovač, Jan Hattendorf, Jennifer Keiser. Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial. Lancet Glob Health. 2017; 5: e688–98. |
| [36] | Wegner, D. H. G. The profile of the trematodicidal compound praziquante. Arzneimittelforschung. 1984; 34: 1132-1136. |
| [37] | Liu R, Dong H-F, Guo Y, Zhao Q-P, Jiang M-S. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors. 2011 Dec; 4 (1): 201. |
| [38] | World Health Organization. Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted helminthiase. Geneva World Health Organ. 2013; |
| [39] | World Health Organization (WHO). Schistosomiasis: Progress Report 2001-2011 and Strategic Plan 2012-2020. Geneva World Health Organ. 2012. |
APA Style
Habtye Bisetegn, Yonas Erkihun. (2020). Efficacy of Praziquantel Treatment for Schistosoma mansoni Infection Among Children in Ethiopia: Systematic Review and Meta-analysis. International Journal of Immunology, 8(4), 61-69. https://doi.org/10.11648/j.iji.20200804.11
ACS Style
Habtye Bisetegn; Yonas Erkihun. Efficacy of Praziquantel Treatment for Schistosoma mansoni Infection Among Children in Ethiopia: Systematic Review and Meta-analysis. Int. J. Immunol. 2020, 8(4), 61-69. doi: 10.11648/j.iji.20200804.11
AMA Style
Habtye Bisetegn, Yonas Erkihun. Efficacy of Praziquantel Treatment for Schistosoma mansoni Infection Among Children in Ethiopia: Systematic Review and Meta-analysis. Int J Immunol. 2020;8(4):61-69. doi: 10.11648/j.iji.20200804.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.iji.20200804.11,
author = {Habtye Bisetegn and Yonas Erkihun},
title = {Efficacy of Praziquantel Treatment for Schistosoma mansoni Infection Among Children in Ethiopia: Systematic Review and Meta-analysis},
journal = {International Journal of Immunology},
volume = {8},
number = {4},
pages = {61-69},
doi = {10.11648/j.iji.20200804.11},
url = {https://doi.org/10.11648/j.iji.20200804.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20200804.11},
abstract = {Background: Schistosomiasis is a chronic neglected tropical disease of poverty caused by blood dwelling trematodes of Schistosoma species. Praziquantel (PZQ) is the current drug of choice for the treatment of human schistosomiasis. The existence of Praziquantel resistance by Schistosoma species is a threat and an alarm for strict monitoring and periodic evaluation of its efficacy. Method: We searched PubMed, PubMed Center, Google Scholar, Web of Science, Google, Science Direct, MEDLINE and proceedings of a professional association to identify studies published in English and assessed the efficacy of Praziquantel against Schistosoma mansoni infection in children. Studies reporting the efficacy of Praziquantel in both adult and children as study participants and studies which investigated the efficacy of Praziquantel combined with other antischistosomal drugs were excluded. Result: Since there was significant heterogeneity, the random effect model was used. A total of 9 papers involving 1,412 participants, that assessed the cure rate and 8 papers that assessed egg reduction rate of Praziquantel were included in the meta-analysis. The pooled cure rate of Praziquantel was 86.65% with 95% CI; 83.4-93.9. There was high heterogeneity (I2=93.4%). Subgroup analysis showed slightly higher Cure rate of Praziquantel in Amhara regional state compared to Oromia regional state (88.58% vs 84.79%). The egg reduction rate was 87.95% and 99.85% using geometric and arithmetic mean of egg count respectively. The prevalence of Schistosoma mansoni decreased from 55.77% to 11.29% after administration of Praziquantel. Conclusion: According to the result of this review, standard dose of Praziquantel was effective against Schistosoma mansoni infection among children in Ethiopia. The cure rate of Praziquantel was slightly higher in Amhara regional state compared to Oromia regional state. The drug showed a great reduction in egg count and intensity of infection.},
year = {2020}
}
TY - JOUR T1 - Efficacy of Praziquantel Treatment for Schistosoma mansoni Infection Among Children in Ethiopia: Systematic Review and Meta-analysis AU - Habtye Bisetegn AU - Yonas Erkihun Y1 - 2020/11/16 PY - 2020 N1 - https://doi.org/10.11648/j.iji.20200804.11 DO - 10.11648/j.iji.20200804.11 T2 - International Journal of Immunology JF - International Journal of Immunology JO - International Journal of Immunology SP - 61 EP - 69 PB - Science Publishing Group SN - 2329-1753 UR - https://doi.org/10.11648/j.iji.20200804.11 AB - Background: Schistosomiasis is a chronic neglected tropical disease of poverty caused by blood dwelling trematodes of Schistosoma species. Praziquantel (PZQ) is the current drug of choice for the treatment of human schistosomiasis. The existence of Praziquantel resistance by Schistosoma species is a threat and an alarm for strict monitoring and periodic evaluation of its efficacy. Method: We searched PubMed, PubMed Center, Google Scholar, Web of Science, Google, Science Direct, MEDLINE and proceedings of a professional association to identify studies published in English and assessed the efficacy of Praziquantel against Schistosoma mansoni infection in children. Studies reporting the efficacy of Praziquantel in both adult and children as study participants and studies which investigated the efficacy of Praziquantel combined with other antischistosomal drugs were excluded. Result: Since there was significant heterogeneity, the random effect model was used. A total of 9 papers involving 1,412 participants, that assessed the cure rate and 8 papers that assessed egg reduction rate of Praziquantel were included in the meta-analysis. The pooled cure rate of Praziquantel was 86.65% with 95% CI; 83.4-93.9. There was high heterogeneity (I2=93.4%). Subgroup analysis showed slightly higher Cure rate of Praziquantel in Amhara regional state compared to Oromia regional state (88.58% vs 84.79%). The egg reduction rate was 87.95% and 99.85% using geometric and arithmetic mean of egg count respectively. The prevalence of Schistosoma mansoni decreased from 55.77% to 11.29% after administration of Praziquantel. Conclusion: According to the result of this review, standard dose of Praziquantel was effective against Schistosoma mansoni infection among children in Ethiopia. The cure rate of Praziquantel was slightly higher in Amhara regional state compared to Oromia regional state. The drug showed a great reduction in egg count and intensity of infection. VL - 8 IS - 4 ER -
Email: